[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630157":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":30,"locations":36,"responsibleParty":177,"collaborators":11,"id":179,"slug":11,"hasResults":180,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":11,"eligibilityCriteria":184,"healthyVolunteers":180,"sex":185,"minAge":186,"maxAge":11,"enrollmentInfo":187,"targetDuration":11,"studyType":190,"phases":191,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},{"fullName":5,"class":6},"Generate Biomedicines","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GB-4362 in Combination With Enfortumab Vedotin and Pembrolizumab","EXPERIMENTAL",null,[13,14,15],"Drug: GB-4362","Drug: enfortumab vedotin (EV)","Drug: Pembrolizumab",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","GB-4362","GB-4362 is an investigational monoclonal antibody",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"enfortumab vedotin (EV)","Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4 that delivers the cytotoxic payload monomethyl auristatin E (MMAE).",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Pembrolizumab","Pembrolizumab is a programmed death-1 (PD-1) immune checkpoint inhibitor administered as standard-of-care therapy for advanced urothelial cancer.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Study Contact","CONTACT","(888) 5471235","clinicaltrials@generatebiomedicines.com",[37,55,66,81,93,105,120,135,148,163],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":45,"coordinates":46},"Point",[47,48],-117.97729,34.13945,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":53,"phoneExt":11,"email":54},"Susan Hmwe Manager Clinical Research","626-218-4081","shmwe@coh.org",{"facility":56,"status":39,"city":57,"state":41,"zip":58,"country":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"COH Lennar","Irvine","92618",{"type":45,"coordinates":60},[61,62],-117.82311,33.66946,{"lat":62,"lon":61},[65],{"name":52,"role":33,"phone":53,"phoneExt":11,"email":54},{"facility":67,"status":39,"city":68,"state":69,"zip":70,"country":43,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Orlando Health","Orlando","Florida","32806",{"type":45,"coordinates":72},[73,74],-81.37924,28.53834,{"lat":74,"lon":73},[77],{"name":78,"role":33,"phone":79,"phoneExt":11,"email":80},"Janice Porter M Clinical Research Screening & Eligibility Manager","321-841-7246","janice.porter@orlandohealth.com",{"facility":82,"status":39,"city":83,"state":84,"zip":85,"country":43,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"COH Atlanta","Tucker","Georgia","30084",{"type":45,"coordinates":87},[88,89],-84.21714,33.85455,{"lat":89,"lon":88},[92],{"name":52,"role":33,"phone":53,"phoneExt":11,"email":54},{"facility":94,"status":39,"city":95,"state":96,"zip":97,"country":43,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"COH Chicago","Zion","Illinois","60099",{"type":45,"coordinates":99},[100,101],-87.83285,42.44613,{"lat":101,"lon":100},[104],{"name":52,"role":33,"phone":53,"phoneExt":11,"email":54},{"facility":106,"status":39,"city":107,"state":108,"zip":109,"country":43,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Rutgers","New Brunswick","New Jersey","22908",{"type":45,"coordinates":111},[112,113],-74.45182,40.48622,{"lat":113,"lon":112},[116],{"name":117,"role":33,"phone":118,"phoneExt":11,"email":119},"Kassie DiOrio Manager","732-454-9795","kassie.diorio@rutgers.edu",{"facility":121,"status":39,"city":122,"state":123,"zip":124,"country":43,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Start New York, LLC","Lake Success","New York","11042",{"type":45,"coordinates":126},[127,128],-73.71763,40.77066,{"lat":128,"lon":127},[131],{"name":132,"role":33,"phone":133,"phoneExt":11,"email":134},"Camilita Goberdhan","347-476-1959","camilita.goberdhan@startresearch.com",{"facility":136,"status":39,"city":123,"state":123,"zip":137,"country":43,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"MSK","10065",{"type":45,"coordinates":139},[140,141],-74.00597,40.71427,{"lat":141,"lon":140},[144],{"name":145,"role":33,"phone":146,"phoneExt":11,"email":147},"Sam Funt PI","646-888-4770","funts@mskcc.org",{"facility":149,"status":39,"city":150,"state":151,"zip":152,"country":43,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"MDACC","Houston","Texas","77030",{"type":45,"coordinates":154},[155,156],-95.36327,29.76328,{"lat":156,"lon":155},[159],{"name":160,"role":33,"phone":161,"phoneExt":11,"email":162},"Cindy Jiang PI","713-876-4652","CYJiang@mdanderson.org",{"facility":164,"status":39,"city":165,"state":166,"zip":109,"country":43,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"The University of Virgina","Charlottesville","Virginia",{"type":45,"coordinates":168},[169,170],-78.47668,38.02931,{"lat":170,"lon":169},[173],{"name":174,"role":33,"phone":175,"phoneExt":11,"email":176},"Clinical Trials Navigator","434-982-0539","uvacancertrials@uva.com",{"type":178,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100630157",false,"NCT07484022","Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered With Enfortumab Vedotin and Pembrolizumab in Participants With Advanced Urothelial Cancer","Inclusion Criteria\n\n* Planned to receive standard-of-care treatment with enfortumab vedotin (EV) (starting dose 1.25 mg\u002Fkg) in combination with pembrolizumab for locally advanced or metastatic urothelial cancer.\n* Age ≥18 years.\n* ECOG Performance Status score of 0 or 1 (ECOG 2 excluded in Dose Escalation but allowed in Dose Expansion).\n* Weight ≥50 kg at screening.\n* Life expectancy ≥3 months, as determined by the investigator.\n* Participants must provide written informed consent before any study-related activities are carried out and must be able to understand the nature and purpose of the study, including potential risks and adverse effects.\n* Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n\nExclusion Criteria\n\n* Previously received enfortumab vedotin (EV) or other MMAE-based antibody-drug conjugates (ADCs).\n* Received anti-cancer treatment with chemotherapy, biologics, or investigational agents within 4 weeks before the first dose of EV\u002Fpembrolizumab.\n* Uncontrolled diabetes.\n* Active CNS metastases. Participants with treated CNS metastases are permitted if all of the following criteria are met:\n* CNS metastases have been clinically stable for at least 4 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis.\n* The participant is on a stable dose of ≤10 mg\u002Fday of prednisone or equivalent for at least 2 weeks (if requiring steroid treatment).\n* The participant does not have leptomeningeal disease.\n* Ongoing clinically significant toxicity associated with prior treatment (including radiotherapy or surgery) that has not resolved to Grade ≤1 or returned to baseline.\n* History of a severe (Grade ≥3) allergic or infusion-related reaction to any monoclonal antibody.\n* Another underlying medical condition that, in the opinion of the investigator, would impair the ability of the participant to receive or tolerate the planned treatment and follow-up.\n* Known psychiatric or substance abuse disorders that would interfere with cooperating with study requirements","ALL","18 Years",{"count":188,"type":189},37,"ESTIMATED","INTERVENTIONAL",[192],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize free monomethyl auristatin E (MMAE), a chemotherapy payload released from enfortumab vedotin that is associated with side effects such as peripheral neuropathy.",[195,196],"Advanced Urothelial Cancer","Metastatic Urothelial Carcinoma",[19,198,27,199,200,201,202,203,204],"Enfortumab Vedotin","Peripheral Neuropathy","Antibody-Drug Conjugate","MMAE","Phase 1 Oncology","Dose Escalation","Dose Expansion","2026-06-17",{"date":207,"type":208},"2026-06-18","ACTUAL",{"date":210,"type":189},"2026-06",{"date":212,"type":189},"2027-12",{"name":5,"class":6},10]